Premenstrual syndrome in adolescents: Diagnosis and treatment

Pediatric Endocrinology Reviews

Volumn 3, Issue SUPPL. 1, 2006, Pages 132-137

  Rapkin, Andrea J ^a   Mikacich, Judith A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Premenstrual dysphoric disorder; Premenstrual syndrome

Indexed keywords

ANTIDEPRESSANT AGENT; CALCIUM CARBONATE; CITALOPRAM; DROSPIRENONE; ETHINYLESTRADIOL; FLUOXETINE; GESTAGEN; GONADORELIN AGONIST; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PAXIL CR; PLACEBO; SERAFEM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; TRYPTOPHAN; VENLAFAXINE; VITEX AGNUS CASTUS EXTRACT;

ADOLESCENT; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; CONFERENCE PAPER; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FORMULATION; EXERCISE; FEMALE; HEALTH EDUCATION; HUMAN; LIFESTYLE; MAJOR DEPRESSION; MOOD DISORDER; PATHOPHYSIOLOGY; PHOTOTHERAPY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY;

ADOLESCENT; ANDROSTENES; CALCIUM; FEMALE; HUMANS; MOOD DISORDERS; PATIENT EDUCATION; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; SPIRONOLACTONE;

EID: 33645383081     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Keye W. Premenstrual syndrome. In: Proceedings of a conference on PMS and related biobehavioral disorders. Published by the BYU Division of Conferences, Provo, UT; 1983:1-10
2. Harrison WM, Rabkin JG, Endicott J. Psychiatric evaluation of premenstrual changes. Psychosomatics 1985;26:789-799
3. Soares CN, Cohen LS, Otto MW, Harlow BL. Characteristics of Women with Premenstrual Dysphoric Disorder (PMDD) Who Did or Did Not Report History of Depression: A Preliminary Report from the Harvard Study of Moods and Cycles. Journal of Women's Health & Gender-based Medicine 2001;10:873-878
4. Montero P, Bernis C, Loukid M, Hilali K, Baali A. Characteristics of menstrual cycles in Moroccan girls: prevalence of dysfunctions and associated behaviours. Ann Hum Biol 1999;26:243-249
5. Wilson C, Emans SJ, Mansfield J, Podolsky C, Grace E. J Adolesc Health Care 1984;5:248-253
6. Wilson CA, Keye WR Jr. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adoles Health Care 1989;10:317-322
7. Shye D, Jaffe B. Prevalence and correlates of perimenstrual symptoms: a study of Istraeli teenage girls. J Adolesc Health 1991;12:217-224
8. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-132
9. Derman O, Kanbur NO, Tokur TE, Kutluk T. Premenstrual syndrome and associated symptoms in adolescent girls. J Obstet Gynecol Reprod Biol 2004;116:201-206
10. Cleckner-Smith CS, Doughty AS, Grossman JA. Premenstrual symptoms. Prevalence and severity in an adolescent sample. J Adolesc Hlth 1998;22:403-408
11. Hammarback S, Damber JE, Backstrom CT. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989;68:125-130
12. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Premenstrual Syndrome. Compendium of Selected Publications 2000;15:1-9 Washington DC.
13. Freeman EW, Schweizer E, Rickels K. Personality factors in women with premenstrual syndrome. Psychpsom Med 1995;57:453-459
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorder-IV, 4th Edition, 1994, Washington, D.C.
15. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990;20:129-134
16. Wilson CA, Turner CW, Keys WR Jr. Firstborn adolescent daughters and mothers with and without premenstrual syndrome: a comparison. J Adolesc Health 1991;12:130-137
17. Perkonigg A, Yonkers KA, Pfister H, Lieb R, Wittchen HU. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004;65:1314-1322
18. Rapkin AJ. Progesterone, GABA and mood disorders in women. Arch Women's Ment Health 1999;2:97-105
19. Rapkin AJ, Mikacich JA. Premenstrual Syndrome: Gynaecology or Psychiatry? Reproductive Medicine Review 2001;9:223-239
20. Sundstrom Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 2003;6:23-41
21. Girdler SS, Straneva PA, Light KC, Pedersen CA, and Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biological Psychiatry 2001;49:788-797
22. Smith SS, Gong QH, Hsu FC, Markowitz RS, French-Mullen JMH, and Li X. GABAA receptor alpha-4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998;392:926-929
23. Sundstrom I, Andersson A, Nyberg S, Ashbrook D, Purdy RH, Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinol 1998;12:16-18
24. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstetrics and Gynecology 1997;90:709-714
25. Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani AD, Luisi M, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;142:269-273
26. Chau JP, Chang AM. Effects of an educational programme on adolescents with premenstrual syndrome. Health Educ Res 1999;14:817-830
27. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Study Group. Am J Obstet Gynecol 1998;179:444-452
28. Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002;23:193-199
29. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M for the PMS/PMDD research group: Evaluation of a unique oral contraceptive in the treatment of Premenstrual Dysphoric Disorder. J Womens Health Gend Based Med 2001;20:561-596
30. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37-51
31. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124-134
32. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 mug on premenstrual symptoms. Contraception 2005;71:1-7
33. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A. The effect of an oral contraceptive containing ethinyl estradiol and drospirenone (Yasmin) on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003;48:79-8
34. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive with Drospirenone in Premenstrual Dysphoric Disorder. Obstet Gynecol 2005;106:492-501
35. Steiner M, Steinberg, S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995;332:1529-1534
36. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Full or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999;19:3-8
37. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatr 1997;58:399-402
38. Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van Erp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol. 2005;193(2):352-356
39. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18:390-398
40. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder. Obstet Gynecol 2001;98:737-744
41. Halbreich U, Bergeron R, Yonders KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-1229
42. Miner C, Brown E, McCray S, Gonzales J, Wahlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clinical Therapeutics 2002;24:417-433
43. Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997;17:261-266
44. Steiner M, Brown E, Trzepacz P, Dillon J, Berger C, Carter D, Reid R, and Stewart D. Fluoxetine improves functional work capacity in women with Premenstrual Dysphoric Disorder. Arch Womens Ment Health 2003;6:71-77
45. Pearlstein T, Joliat MJ, Brown EB, Miner CM. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am J Obstet Gynecol 2003;188:887-895
46. Scahill L, Hamrin V, Pachler ME. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. J. Child Adolesc Psychiatr Nurs 2005;18:86-89
47. Rowe L, Tonge B, Melvin G. When should GPs prescribe SSRIs for adolescent depression? Aust Fam Physician 2004;33:1005-1008
48. Doggrell SA. Fluoxetine - do the benefits outweigh the risks in adolescent major depression? Expert Opin Pharmacother 2005;6:147-1450
49. Ginsburg KA, Dinsay R. Premenstrual syndrome. In: Ransom SB, ed. Practical Strategies In Obstetrics and Gynecology. Philadelphia: W.B. Saunders Company, 2000:684-694
50. Vellacott ID, Shroff NE, Pearce MY, Stratford ME, Akbar FA. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987;10:450-456
51. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995;74:803-808
52. Muse KN, Cetel NS, Futterman LA, Yen SSC. The premenstrual syndrome - Effects of "medical ovariectomy." N Engl J Med 1984;311:1345-1349
53. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991;71:252a-252F
54. Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994;62:932-937
55. Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Research 1999;86:185-192
56. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003;188:S56-65
57. Steinberg S, Annable L, Young SN, Liyanage N. A Placebo-Controlled Clinical Trial of L-Tryptophan in Premenstrual Dysphoria. Biol Psychiatry 1999;45:313-320
58. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine 2003;10:348-357
59. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001;322(7279):134-137